Disease modeling and lentiviral gene transfer in patient-specific induced pluripotent stem cells from late-onset Pompe disease patient

Molecular Therapy Methods and Clinical Development

Volumn 2, Issue , 2015, Pages 15023-

  Sato, Yohei ^a   Kobayashi, Hiroshi ^a   Higuchi, Takashi ^a   Shimada, Yohta ^a   Era, Takumi ^b   Kimura, Shigemi ^b   Eto, Yoshikatsu ^c   Ida, Hiroyuki ^a   Ohashi, Toya ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c Institute of Neurological Disorders   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAN 1,4 ALPHA GLUCOSIDASE; GLYCOGEN; ALPHA FETOPROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEPATOCYTE NUCLEAR FACTOR 3BETA; LENTIVIRUS VECTOR; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MICROTUBULE ASSOCIATED PROTEIN 2; STAGE SPECIFIC EMBRYO ANTIGEN 4; TRANSCRIPTION FACTOR MSX1; TRANSCRIPTION FACTOR OTX2; TRANSCRIPTION FACTOR PAX6; TRANSCRIPTION FACTOR SOX17;

ARTICLE; CARDIAC MUSCLE CELL; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; ENZYME ACTIVITY; GENE THERAPY; GENE TRANSFER; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; HUMAN CELL; INDUCED PLURIPOTENT STEM CELL; LENTIVIRINAE; PRIORITY JOURNAL; VIRUS GENE; CONTROLLED STUDY; DISEASE MODEL; ECTODERM; EMBRYOID BODY; ENDODERM; GENE DOSAGE; GENE MUTATION; GLYCOGEN ANALYSIS; IN VITRO STUDY; LATE ONSET DISORDER; MESODERM; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRAL GENE DELIVERY SYSTEM;

EID: 84962932527     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2015.23     Document Type: Article

References (23)

1. 1 Hers, HG, Alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe's disease). Biochem J 86 (1963), 11–16.
2. 2 Kishnani, PS, Howell, RR, Pompe disease in infants and children. J Pediatr 144:5 Suppl (2004), S35–S43.
3. 3 Kishnani, PS, Corzo, D, Nicolino, M, Byrne, B, Mandel, H, Hwu, WL, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68 (2007), 99–109.
4. 4 van der Ploeg, AT, Clemens, PR, Corzo, D, Escolar, DM, Florence, J, Groeneveld, GJ, et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 362 (2010), 1396–1406.
5. 5 Aiuti, A, Biasco, L, Scaramuzza, S, Ferrua, F, Cicalese, MP, Baricordi, C, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science, 341, 2013, 1233151.
6. 6 Biffi, A, Montini, E, Lorioli, L, Cesani, M, Fumagalli, F, Plati, T, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science, 341, 2013, 1233158.
7. 7 Khanna, R, Powe, AC Jr, Lun, Y, Soska, R, Feng, J, Dhulipala, R, et al. The pharmacological chaperone AT2220 increases the specific activity and lysosomal delivery of mutant acid alpha-glucosidase, and promotes glycogen reduction in a transgenic mouse model of Pompe disease. PLoS One, 9, 2014, e102092.
8. 8 Huang, HP, Chen, PH, Hwu, WL, Chuang, CY, Chien, YH, Stone, L, et al. Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification. Hum Mol Genet 20 (2011), 4851–4864.
9. 9 Forsha, D, Li, JS, Smith, PB, van der Ploeg, AT, Kishnani, P, Pasquali, SK, Late-Onset Treatment Study Investigators. Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy. Genet Med 13 (2011), 625–631.
10. 10 Hobson-Webb, LD, Proia, AD, Thurberg, BL, Banugaria, S, Prater, SN, Kishnani, PS, Autopsy findings in late-onset Pompe disease: a case report and systematic review of the literature. Mol Genet Metab 106 (2012), 462–469.
11. 11 Fox, IJ, Daley, GQ, Goldman, SA, Huard, J, Kamp, TJ, Trucco, M, Stem cell therapy. Use of differentiated pluripotent stem cells as replacement therapy for treating disease. Science, 345, 2014, 1247391.
12. 12 Lee, DH, Qiu, WJ, Lee, J, Chien, YH, Hwu, WL, Hypertrophic cardiomyopathy in pompe disease is not limited to the classic infantile-onset phenotype. JIMD Rep 17 (2014), 71–75.
13. 13 Priori, SG, Napolitano, C, Di Pasquale, E, Condorelli, G, Induced pluripotent stem cell-derived cardiomyocytes in studies of inherited arrhythmias. J Clin Invest 123 (2013), 84–91.
14. 14 Garate, Z, Davis, BR, Quintana-Bustamante, O, Segovia, JC, New frontier in regenerative medicine: site-specific gene correction in patient-specific induced pluripotent stem cells. Hum Gene Ther 24 (2013), 571–583.
15. 15 Raben, N, Schreiner, C, Baum, R, Takikita, S, Xu, S, Xie, T, et al. Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder–murine Pompe disease. Autophagy 6 (2010), 1078–1089.
16. 16 Kishnani, PS, Goldenberg, PC, DeArmey, SL, Heller, J, Benjamin, D, Young, S, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 99 (2010), 26–33.
17. 17 Kyosen, SO, Iizuka, S, Kobayashi, H, Kimura, T, Fukuda, T, Shen, J, et al. Neonatal gene transfer using lentiviral vector for murine Pompe disease: long-term expression and glycogen reduction. Gene Ther 17 (2010), 521–530.
18. 18 Tedesco, FS, Gerli, MF, Perani, L, Benedetti, S, Ungaro, F, Cassano, M, et al. Transplantation of genetically corrected human iPSC-derived progenitors in mice with limb-girdle muscular dystrophy. Sci Transl Med, 4, 2012, 140ra89.
19. 19 Filareto, A, Parker, S, Darabi, R, Borges, L, Iacovino, M, Schaaf, T, et al. An ex vivo gene therapy approach to treat muscular dystrophy using inducible pluripotent stem cells. Nat Commun, 4, 2013, 1549.
20. 20 Ono, M, Hamada, Y, Horiuchi, Y, Matsuo-Takasaki, M, Imoto, Y, Satomi, K, et al. Generation of induced pluripotent stem cells from human nasal epithelial cells using a Sendai virus vector. PLoS One, 7, 2012, e42855.
21. 21 Hamasaki, M, Hashizume, Y, Yamada, Y, Katayama, T, Hohjoh, H, Fusaki, N, et al. Pathogenic mutation of ALK2 inhibits induced pluripotent stem cell reprogramming and maintenance: mechanisms of reprogramming and strategy for drug identification. Stem Cells 30 (2012), 2437–2449.
22. 22 Takahashi, K, Tanabe, K, Ohnuki, M, Narita, M, Ichisaka, T, Tomoda, K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 (2007), 861–872.
23. 23 Minami, I, Yamada, K, Otsuji, TG, Yamamoto, T, Shen, Y, Otsuka, S, et al. A small molecule that promotes cardiac differentiation of human pluripotent stem cells under defined, cytokine- and xeno-free conditions. Cell Rep 2 (2012), 1448–1460.